加速脉冲高能量角膜交联术治疗进展性圆锥角膜的两年结果
本研究为前瞻性介入病例系列,纳入870例(1192眼)进展性圆锥角膜患者,接受Avedro KXL系统加速脉冲高能量CXL(30 mW/cm²,4分钟,总能量7.2 J/cm²)。
要点
- 加速脉冲高能量CXL可稳定98.3%进展性圆锥角膜患眼的角膜曲率。
- CDVA、主觉验光和内皮细胞密度无显著变化,2.7%患眼CDVA下降超过2行。
核心结论
- 加速脉冲高能量CXL在2年随访中安全、有效且屈光中性,可阻止圆锥角膜进展。
研究设计与样本
- 前瞻性介入病例系列,纳入Moorfields眼科医院870例(1192眼)进展性圆锥角膜患者。
- 排除最小基质厚度<375 μm的角膜,核黄素0.1%浸泡10分钟。
- 高能量脉冲UVA 30 mW/cm²照射4分钟,1.5秒开/关周期,总能量7.2 J/cm²。
- 基线和术后6、12、24个月进行主觉验光、角膜断层扫描和角膜内皮镜检。
- 主要结局为24个月最大角膜曲率(Kmax)变化。
主要发现
- 12个月和24个月随访数据分别来自543例和213例患者,平均年龄25.4±6.6岁。
- 轻度圆锥(Kmax<55 D)24个月平均角膜曲率保持不变。
- 98.3%患眼角膜曲率稳定得到确认。
- 平均CDVA、主觉验光和内皮细胞密度无变化,2.7%患眼CDVA下降超过2行。
关键数值与推荐
- 纳入标准为进展性圆锥角膜,排除最小基质厚度<375 μm。
- 核黄素0.1%浸泡10分钟,UVA 30 mW/cm²照射4分钟,总能量7.2 J/cm²。
- 轻度圆锥(Kmax<55 D)24个月平均角膜曲率不变。
- 98.3%患眼角膜曲率稳定,2.7%患眼CDVA下降超过2行。
临床怎么用
- 加速脉冲高能量CXL可用于阻止进展性圆锥角膜进展,2年内屈光中性。
- 对轻度圆锥角膜(Kmax<55 D)可维持角膜曲率稳定。
- 对晚期病例可预期轻度角膜变平,但需关注2.7%患眼CDVA下降超过2行的风险。
局限性
- 24个月随访数据仅来自213例患者,样本量较基线明显减少。
- 本研究为病例系列,无对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report on 2-year results of accelerated corneal collagen cross-linking (CXL) in progressive ectasia using the Avedro KXL system. DESIGN: Prospective interventional case series. METHODS: A total of 870 patients (1,192 eyes) attending Moorfields Eye Hospital after CXL were included. All patients undergoing CXL had progressive keratoconus. Corneas with a minimum stromal thickness <375 μm were excluded. Riboflavin 0.1% soak duration was 10 minutes. High-fluence pulsed UVA was delivered at 30 mW/cm2 for 4 minutes, with a 1.5-second on/off cycle (total energy 7.2 J/cm2). Subjective refractive, corneal tomography, and specular microscopy were performed at baseline, 6, 12, and 24 months postoperatively. The primary outcome measure was a change in maximum keratometry (Kmax) at 24 months. RESULTS: Twelve- and 24-month follow-up data were available on 543 and 213 patients, respectively (mean age 25.4 ± 6.6 years). In mild cones (Kmax < 55 diopter [D]), mean keratometry remained unchanged at 24 months. In more advanced disease, we observed modest corneal flattening compared to baseline (Kmax 63.2 ± 6.5 D vs 61.9 ± 8.1 D, P = .02), but no significant changes in central keratometry (K1 or K2). Keratometric stabilization was confirmed in 98.3% of eyes. Mean CDVA, manifest refraction and endothelial cell density did not change. Overall, 2.7% of eyes lost more than 2 lines of CDVA. CONCLUSION: Accelerated pulsed CXL is a safe, effective, and refractively neutral intervention (at 2 years) to halt disease progression in keratoconus.
引用
- Gore DM, Leucci MT, Koay SY, et al. Accelerated Pulsed High-Fluence Corneal Cross-Linking for Progressive Keratoconus. Am J Ophthalmol. 2020. PMID: 32818448. doi:10.1016/j.ajo.2020.08.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。